Express Healthcare
Home  »  News  »  NephroPlus set to expand services in West Asia and South East Asia

NephroPlus set to expand services in West Asia and South East Asia

The dialysis provider raised Rs 323 crore from Bahrain-based private equity player, Investcorp

0 123
Read Article

Setting sights on expanding their services in dialysis care, NephroPlus is foraying into international markets beginning with West Asia and South East Asia. The centre that is focussed at redefining dialysis treatment, received an investment of $45 million (Rs 323 crore) from Investcorp, a Bahrain-based, global alternative asset management company.

With a footprint of a notable dialysis network in the country with over 200 centres, NephroPlus has been providing cost-effective treatments to over 14,000 dialysis patients. With the latest investment, the company is looking at expanding beyond their current presence in 20 states of India. The funds will further be for acquisitions and partnerships commencing with Indonesia, Philippines, Vietnam, Saudi Arabia and Bahrain. A contract with Vietnam is currently underway and will be effective within the next two- three months.

The focus for the Indian market will continue to develop through the dialysis programmes currently on track at 180 hospitals and will subsequently continue through select acquisitions and expansion of centres; joint ventures and new operation and maintenance contracts will also be set in motion.

Speaking about the big-ticket announcement, Vikram Vuppala, Founder and CEO, NephroPlus, said, “We are excited on this newest development, our partnership with Investcorp will help transform the healthcare industries in India and overseas. With our current growth rate through our existing services, we are now aiming at a rapid growth through this investment.”

Further commenting on the company’s hindsight of future developments in Indian and international markets, Vuppala says, “Through acquisitions and joint ventures, we are hoping to set-up 75-100 centres in the five international markets within the next three years. In India, we are aiming to grow momentum by expanding to 40 centres every year through our high-quality, but cost-effective models.”

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More